Sapanisertib

在探索人类疾病与药物研发的征途中，动物模型是不可或缺的“替身”。它们帮助科学家在将新疗法推向临床之前，验证安全性与有效性。在众多实验动物中，食蟹猴与斑马鱼凭借各自独特的生物学优势，犹如一大一小两位“功臣”，在医学科研领域扮演着至关重要的角色。一个承载着与人类高度相似的基因密码，一个以透明的身躯揭示生命的动态奥秘，二者相辅相成，共同筑起了从实验室到病床前的坚实桥梁。食蟹猴——与人类“同根同源”的精密验证官高度相似的基因与生理特征食蟹猴属于非人灵长类，是衔接基础研究与临床应用的重要纽带。食蟹猴与人类的基因同源性高达93%，其组织结构、免疫系统、代谢通路乃至神经系统均与人类高度相似。食蟹猴的脂蛋白和心血管系统与人类相似，其动脉粥样硬化的发病进展过程也高度模拟人类病程，这种相似性远超啮齿类动物。在代谢研究中，食蟹猴会患自发性肥胖症，其腹部脂肪细胞代谢与人体脂肪细胞代谢十分相似，是研究二型糖尿病、代谢综合征的理想模型。核心优势：高转化价值正是由于这种遗传与生理的贴近，食蟹猴模型得出的实验结果转化价值极高，能有效降低药物从临床前研究向人体临床试验的风险。它更真实地模拟了人类疾病的病理生理过程及药物在人体内的吸收、分布、代谢与毒理反应。广泛应用场景在应用层面，食蟹猴凭借与人类高度相似的遗传与生理背景，在神经退行性疾病、免疫药物评价及罕见病研究中占据核心地位。其基因编辑模型能真实再现帕金森病的震颤症状和阿尔茨海默病的早期生物标志物变化，同时有效预测免疫治疗药物的临床毒性风险，并成功填补了多项罕见病动物模型的长期空白。斑马鱼——“水中小白鼠”的高效筛选先锋透明的“活体观察窗”斑马鱼虽然体型小巧，但约 有‌87%‌ 的基因与人类基因存在对应关系 。更神奇的是，斑马鱼的胚胎在体外发育且通体透明。这种透明度让研究者能像看“直播”一样，实时观察药物对器官发育、细胞行为及基因表达的影响。核心优势：高通量与低成本斑马鱼单次产卵可达数百枚，繁殖速度快、饲养成本低，非常适合高通量药物筛选。它有效遵循了国际通行的3R原则（替代、减少、优化），降低了科研对哺乳动物模型的依赖。广泛应用场景在应用层面，斑马鱼的心血管系统与人类具有相似性，加之胚胎透明的特点，使其被广泛用于模拟心脏病、肥胖症及2型糖尿病等代谢性疾病的研究。同时，斑马鱼模型凭借其高效性，被医药研发机构普遍用于药物疗效与安全性评价，例如科学家曾利用早衰症斑马鱼模型，通过小规模筛选快速发现了抗癌药物sapanisertib的抗衰老潜力。此外，借助CRISPR/Cas9等基因编辑工具，斑马鱼还能精准模拟特定基因突变，用于解析罕见病、癌症和血液病等疾病的致病机理。结语食蟹猴与斑马鱼，一个代表精准与转化，一个代表效率与可视。食蟹猴以其与人类的高度相似性，成为药物临床前研究中最关键的“把关人”；斑马鱼则凭借基因同源与胚胎透明的独特优势，成为基因解析和药物筛选的“急先锋”。二者相辅相成，共同搭建了从基础发现到临床转化的完整桥梁，推动着现代医学不断前行。如需了解更多关于食蟹猴或斑马鱼模型的相关服务，欢迎随时联系我。

— Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement — — Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock expected to begin trading under the ticker symbol “FTH” on June 16, 2026 — — Anand Parikh, Faeth co-founder, appointed Chairman, President and Chief Executive Officer; Brian Stephenson, Ph.D., CFA appointed Chief Financial Officer; board strengthened with the addition of former FDA Commissioner Stephen M. Hahn, M.D., and Saira Ramasastry — — PIKTOR, an investigational all-oral multi-node inhibitor of the PI3K/AKT/mTOR pathway, on track for topline Phase 2 data in advanced endometrial cancer in the second half of 2026 — AUSTIN, Texas--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has changed its corporate name to Faeth Therapeutics, Inc. (the “Company”). The Company’s common stock is expected to begin trading on the Nasdaq Capital Market under the new ticker symbol “ FTH ” on June 16, 2026, and the Company has launched a new corporate website at . On June 10, 2026, stockholders approved the conversion of the Company’s Series B preferred stock issued in connection with the February 2026 acquisition of Faeth Therapeutics and concurrent private placement. As a result, outstanding shares of the Company’s Series B convertible preferred stock will automatically convert into common stock effective at 5:00 p.m. ET on June 15, 2026, subject to certain beneficial ownership limitations set by each holder. The Company received approximately $200 million in gross proceeds from the private placement that closed concurrently with its February 2026 acquisition of Faeth. “Starting tomorrow, we will begin trading on Nasdaq under our new name and ticker as a well-capitalized public company backed by a syndicate of leading life sciences investors, and focused on a clear set of clinical catalysts,” said Anand Parikh, Chairman and Chief Executive Officer. “For two decades, drugs that block a single node of the PI3K/AKT/mTOR pathway have been undone by the tumor’s ability to route around them. PIKTOR represents our answer to this challenge: an all-oral regimen that patients can take at home, designed to inhibit PI3K-alpha, mTORC1 and mTORC2 at once, close the routes tumors may use to escape, and potentially drive deeper, more durable suppression, with the potential for a best-in-class profile. We believe we now have the capital and the team to put that approach to the test, beginning with topline Phase 2 data in advanced endometrial cancer, expected in the second half of this year, and interim Phase 1b/2 data in HR+/HER2- advanced breast cancer, expected in 2027.” Leadership and Board Effective June 12, 2026, the Company appointed a new executive leadership team. Anand Parikh, a co-founder of Faeth who has led the company since its founding in 2019, has been appointed Chairman, President and Chief Executive Officer. Brian Stephenson, Ph.D., CFA, who previously served as the Company’s Head of Operations and Finance and as Chief Financial Officer of BridgeBio Pharma, Inc., has been appointed Chief Financial Officer. Oliver Maddocks, Ph.D., a co-founder of Faeth and a cancer-metabolism researcher, serves as Chief Scientific Officer, and Debbie Chirnomas, M.D., M.P.H., serves as Chief Medical Officer. The Company’s board of directors consists of five members: Anand Parikh (Chair); Bob Holmen; Phillip B. Donenberg; Stephen M. Hahn, M.D.; and Saira Ramasastry. Dr. Hahn, the 24th Commissioner of the U.S. Food and Drug Administration and a former Faeth director, and Ms. Ramasastry, a life sciences strategic advisor and experienced public-company director, joined the board on June 12, 2026. “In a career spent in oncology and at the FDA, I’ve learned how rarely a program pairs a high-prevalence target with a potentially differentiated mechanism,” said Stephen M. Hahn, M.D., the 24th Commissioner of the U.S. Food and Drug Administration and a member of the Company’s board of directors. “I believe Faeth’s multi-node, all-oral approach to the PI3K/AKT/mTOR pathway is scientifically rigorous and aimed at a real unmet need. I’m looking forward to guiding the company through this next stage of clinical development.” About PIKTOR PIKTOR is an investigational, proprietary, all-oral combination of serabelisib, a selective PI3K-alpha inhibitor, and sapanisertib, an mTORC1/mTORC2 inhibitor, designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway. According to published literature, this pathway is dysregulated in up to 50% of all solid tumors, making it one of the most prevalent therapeutic targets in oncology. PIKTOR is being evaluated in a Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201), with topline data anticipated in the second half of 2026, and in a Phase 1b/2 trial in HR+/HER2- advanced breast cancer (Study FTH-PIK-101), in which the first patient was dosed in April 2026 and interim data is anticipated in 2027. About Faeth Therapeutics Faeth Therapeutics, Inc. (Nasdaq: FTH) is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company’s lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. Faeth was co-founded in 2019 by Anand Parikh and Oliver Maddocks, Ph.D., together with scientific founders Lewis Cantley, Ph.D., the discoverer of the PI3K pathway; Siddhartha Mukherjee, M.D., D.Phil.; Karen Vousden, Ph.D.; Scott Lowe, Ph.D.; and Greg Hannon, Ph.D. The Company intends to use its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, please visit and follow the Company on LinkedIn . Cautionary Note Regarding Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” “may,” “will,” “would,” “could,” “should,” “estimate,” “potential,” “target,” “on track” and similar expressions, although not all forward-looking statements contain these words. These statements include, but are not limited to, statements regarding: the change of the Company’s corporate name to Faeth Therapeutics, Inc.; the expected commencement of trading of the Company’s common stock under the new name and ticker symbol “FTH” and the timing thereof; the Company’s expectations regarding its pipeline and development plans, including the Phase 2 trial of PIKTOR in advanced endometrial cancer and the anticipated timing of topline data, and the Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer and the anticipated timing of interim data; the potential therapeutic benefits, tolerability pro differentiation of PIKTOR; and the Company’s expectations regarding its cash runway. Forward-looking statements are based on management’s current expectations and assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, risks related to clinical development and the conduct, timing and results of clinical trials; the Company’s need for additional financing; its limited operating history and history of operating losses; risks related to the integration of Faeth; the Company’s ability to satisfy applicable Nasdaq listing requirements and to maintain the listing of its common stock; and the other risks and uncertainties described under the headings “Risk Factors” and “Summary of Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2026, its Quarterly Report on Form 10-Q filed with the SEC on May 15, 2026, and its definitive proxy statement filed with the SEC on April 27, 2026, as well as in the Company’s subsequent filings. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required by law. Contacts Investor Contact: Matthew Biegler, SVP, Investor Relations matt@faeththerapeutics.com Stephanie Ascher, Precision AQ stephanie.ascher@precisionaq.com Media Contact: Patrick Schmidt, Consort Partners faeththerapeutics@consortpartners.com